Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime-Zidebactam vs Ceftazidime-avibactam in HABP/VABP
NCT07885891Phase 3Not yet recruiting
- Sponsor
- Wockhardt
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Countries
- 14
01
Overview
A Phase 3 trial of cefepime + zidebactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Wockhardt. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
cefepime + zidebactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT07885891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885891.